Overview

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Status:
RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left ventricular endocardial border delineation compared with unenhanced echocardiography. The study also aims to investigate the safety and tolerability of NH002.
Phase:
PHASE3
Details
Lead Sponsor:
Trust Bio-sonics, Inc.
Collaborator:
CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH